135062-02-1 (瑞格列奈,Repaglinide)

瑞格列奈;(S)-2-乙氧基-4-[2-[3-甲基-1-[2-(1-哌啶基)苯基]-丁烷基]-氨基]-2-羰乙基苯甲酸;诺和龙;(S)-2-乙氧基-4-[2-[[3-甲基-1-[2-(1-哌啶)苯基]丁基]氨基]-2-氧乙基]苯甲酸;瑞哌格列尼;瑞格列奈基]丁基]氨基]-2-氧乙基]苯甲酸;瑞格列奈(标准品);2-(4-氯苯基)苯乙酮;3-甲基-1-(4-硫代酰氨基苯基)-5-吡唑酮;Repaglinide; 瑞格列奈;S(+)-2-乙氧基-4-{2-[(3-甲基-1-(2-(1-哌啶基)苯基)丁基)氨基];瑞格列奈 EP标准品;瑞格列奈 Repaglinide;瑞格列奈 USP标准品;瑞格列奈 标准品;瑞格列奈,诺和龙;瑞格列奈及杂质;瑞格列奈系统适用性 EP标准品;瑞格列奈杂质;瑞格列奈杂质对照品;消旋瑞格列奈;S(+)-2-乙氧基-4-{2-[(3-甲基-1-(2-(1-哌啶基)苯基)丁基)氨基]};瑞格列萘;(S)-(+)-2-乙氧基-4-[N-[1-(2-哌啶苯基)-3-甲基-1-丁基]氨基羰基甲基]苯甲酸;

(S)-2-Ethoxy-4-(2-((3-methyl-1-(2-(piperidin-1-yl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid;4-Ethoxycarbonyl-3-ethoxy phenyl acetic acid;AG-EE 623ZW;Repaglinide;2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid;2-Ethoxy-4-[2-[[(1S)-3-Methyl-1-[2-(1-Piperidinyl)Phenyl]Butyl]Amino]-2-Oxoethyl]Benzoic Acid;Prandin,GlucoNorm,NovoNorm;(S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid;Novonorm;Prandin;GlucoNorm;Repaglinidum;Repaglinida;Repaglinidum [INN-Latin];Repaglinida [INN-Spanish];C27H36N2O4;668Z8C33LU;2-Ethoxy-4-[2-[[(1S)-3-Methyl-1-[2-(1-Piperidinyl)Phenyl]Buty;AKOS005561792;BRD-K82846253-001-03-0;(S)-2-ETHOXY-4-(2-(METHYL-1-(2-(1-PIPERIDINYL)PHENYL)BUTYLAMINO)-2-OXOETHYL)-BENZOIC ACID;REPAGLINIDE [VANDF];HMS3414D09;Q2195995;2-ethoxy-4-[2-({(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl}amino)-2-oxoethyl]benzoic acid;SW197344-4;Repaglinide for system suitability, European Pharmacopoeia (EP) Reference Standard;BJX;Q-201663;AM20090697;2-ethoxy-4-({[(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]carbamoyl}methyl)benzoic acid;HMS2094C07;NN-623;F15001;BIDD:GT0338;Prestwick3_001046;SMR000466305;Reglin;(S)-2-Ethoxy-4-(2-((3-methyl-1-(2-(piperidin-1-yl)phenyl)butyl)amino)-2-oxoethyl)benzoicacid;REPAGLINIDE (MART.);Repaglinida (INN-Spanish);(+)-2-Ethoxy-alpha-(((S)-alpha-isobutyl-o-piperidinobenzyl)carbamoyl)-p-toluic acid;Benzoic Acid, 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-,(S)-;Surepost;Benzoic acid, 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-, (S)-;A10BX02;AG-EE 623 ZW;SMP-508;AG-EE-623-ZW;MLS000759407;repa-glinide;Repaglinide [USAN:USP:INN:BAN];REPAGLINIDE [USP MONOGRAPH];NCGC00016978-05;REPAGLINIDE (EP MONOGRAPH);(S)-2-Ethoxy-4-[N-(1-(2-piperidino-phenyl)-3-methyl-1-butyl)-aminocarbonylmethyl]-benzoic acid;s1426;BDBM50153520;Z1501485370;AB00514019_10;(S)-2-Ethoxy-4-(2-(3-methyl-1-(2-piperidinophenyl)butylamino)-2-oxoethyl)benzoic acid;111GE012;Actulin;CCG-101013;FAEKWTJYAYMJKF-QHCPKHFHSA-N;AB00514019_11;SBI-0206942.P001;SPBio_002906;D00594;Repaglinide [USAN];MLS001424111;AB00514019-09;Repaglinide, European Pharmacopoeia (EP) Reference Standard;Tox21_110721;BPBio1_001070;GTPL6841;NSC 759893;Pharmakon1600-01506035;BCP04250;AG-EE 388 ZW;Repaglinide for system suitability;Repaglinide, United States Pharmacopeia (USP) Reference Standard;(S)-2-Ethoxy-4-[2-[[3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid;NCGC00016978-02;AG-EE-623 ZW;Repaglinide (JAN/USP/INN);HMS3678D09;(-)-Repaglinide;SCHEMBL16137;A806877;AC-726;(S)-2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)-phenyl)butyl)amino)-2-oxoethyl)-benzoic acid;MFCD00906179;BSPBio_000972;HB1106;(S)-2-ethoxy-4-(2-(3-methyl-1-(2-(piperidin-1-yl)phenyl)butylamino)-2-oxoethyl)benzoic acid;AG-EE-388;REPAGLINIDE [MI];REPAGLINIDE [MART.];2-Ethoxy-4-[2-[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benz oic acid;HMS2098A14;REPAGLINIDE [JAN];Repaglinide,(S);BR164332;AGEE-623ZW;HMS2231M21;NCGC00016978-01;(+)-2-ETHOXY-.ALPHA.-(((S)-.ALPHA.-ISOBUTYL-O-PIPERIDINOBENZYL)CARBAMOYL)-P-TOLUIC ACID;REPAGLINIDE [EMA EPAR];REPAGLINIDE [INN];HMS3715A14;HMS2051N08;Repaglinide (USAN:USP:INN:BAN);REPAGLINIDE (USP MONOGRAPH);C07670;AB00514019;REPAGLINIDE (USP-RS);BS-1010;Repaglinide, >=98% (HPLC), solid;135062-02-1;CHEMBL1272;CHEBI:8805;SR-01000759404-4;HY-15209;(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-5-guanidino-pentanoyl]amino]-4-carboxy-butanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]acetyl]amino]-4-methyl-pentanoyl]amino]-3-methyl-pe;(S)-2-Ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidyl)phenyl]butyl]amino]-2-oxoethyl]benzoic Acid;Prestwick1_001046;2-ethoxy-4-(2-{[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino}-2-oxoethyl)benzoic acid;(s)-(+)-2-ethoxy-4-(2-oxo-2-[(alpha-isobutyl-2-piperidinobenzyl)amino]ethyl)-benzoic acid;Prestwick2_001046;HMS1571A14;REPAGLINIDE [ORANGE BOOK];NSC-759893;(S)-2-Ethoxy-4-[2-[[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzoic Acid;CAS-135062-02-1;Prestwick0_001046;UNII-668Z8C33LU;DB00912;DTXCID603552;Prandin (TN);MLS006011560;Repaglinidum (INN-Latin);Surepost (TN);CS-0979;DTXSID3023552;REPAGLINIDE [USP-RS];NSC759893;(+)-repaglinide;AG-EE-623ZW;MLS001076684;REPAGLINIDE [EP MONOGRAPH];R0179;REPAGLINIDE [WHO-DD];(S)-2-Ethoxy-4-(2-((methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-benzoic acid;Benzoic acid, 2-ethoxy-4-[2-[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]-;NCGC00016978-04;SR-01000759404;Repaglinide- Bio-X;NC00263;2-Ethoxy-4-{[(S)-3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl]-methyl}-benzoic acid;BRD-K82846253-001-14-7;BRD-K82846253-001-15-4;BRD-K82846253-001-16-2;NCGC00016978-15;STK629501;

MFCD00906179

FAEKWTJYAYMJKF-QHCPKHFHSA-N

1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1

O=C(C([H])([H])C1C([H])=C([H])C(C(=O)O[H])=C(C=1[H])OC([H])([H])C([H])([H])[H])N([H])[C@@]([H])(C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1N1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H]

24724596

2933399090

瑞格列奈用于治疗2型糖尿病。

3-甲基-1-[2-(1-哌啶)苯基]丁胺转化为N-乙酰基衍生物后，再通过和L-谷氨酸成盐拆分得到(S)型的旋光异构体，然后和3-乙氧基-4-乙氧羰基苯乙酸进行酰化反应形成酰胺，再水解得到产物。

8238956

MFCD00906179